Invitae Corporation (NVTA) News

Invitae Corporation (NVTA): $2.84

-0.13 (-4.38%)

POWR Rating

Component Grades













Filter NVTA News Items

NVTA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVTA News Highlights

  • For NVTA, its 30 day story count is now at 13.
  • Over the past 17 days, the trend for NVTA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • ACT, HUGE and ROSE are the most mentioned tickers in articles about NVTA.

Latest NVTA News From Around the Web

Below are the latest news stories about INVITAE CORP that investors may wish to consider to help them evaluate NVTA as an investment opportunity.

Why Shares of Invitae Rose 11% on Tuesday

Shares of medical genetics testing company Invitae (NYSE: NVTA) rose 11% on Tuesday. Invitate didn't have any announcements on Tuesday, though it is presenting research this week in Nashville, Tennessee, at the National Society of Genetic Counselors conference. Invitae reported revenue of $133.5 million, up 16.7%, year over year.

Yahoo | November 16, 2022

More Likely to 5X First: Teladoc vs. Invitae

Two stocks that could climb fivefold if they make progress toward their goals are Teladoc Health (NYSE: TDOC) and Invitae (NYSE: NVTA). Teladoc and Invitae shares both have lost more than 70% this year. Teladoc disappointed investors with two massive noncash goodwill impairment charges linked to an acquisition.

Yahoo | November 12, 2022

Invitae Showcases Advances in Medical Genomics at the National Society of Genetic Counselors (NSGC) 41st Annual Conference

Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are presenting research next week at the National Society of Genetic Counselors (NSGC) 41st Annual Conference in Nashville enabling the progress of the science and practice of genetics in patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award, which recognizes excellence in the field of genetic counseling.

Yahoo | November 10, 2022

Invitae Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Invitae ( NYSE:NVTA ) Third Quarter 2022 Results Key Financial Results Revenue: US$133.5m (up 17% from 3Q 2021). Net...

Yahoo | November 10, 2022

Invitae (NVTA) Receives a Hold from SVB Securities

SVB Securities analyst Puneet Souda maintained a Hold rating on Invitae (NVTA - Research Report) today and set a price target of $3.00. The company's shares closed yesterday at $2.35.According to TipRanks, Souda is an analyst with an average return of -12.0% and a 36.14% success rate. Souda covers the Healthcare sector, focusing on stocks such as Illumina, Agilent, and Myriad Genetics.Invitae has an analyst consensus of Moderate Sell, with a price target consensus of $2.56.See the top stocks recommended by analysts >>The company has a one-year high of $22.58 and a one-year low of $1.83. Currently, Invitae has an average volume of 18.18M.

Carrie Williams on TipRanks | November 9, 2022

Why Invitae Stock Is Crushing It Today

Invitae (NYSE: NVTA) stock was absolutely crushing it on Wednesday, with its shares skyrocketing 19.4% higher as of 11:11 a.m. ET. The huge gain came after the medical genetics company announced its third-quarter results following the market close on Tuesday. Invitae posted a net loss of $301.2 million, or $1.27 per share, based on generally accepted accounting principles (GAAP).

Yahoo | November 9, 2022

Invitae (NVTA) Q3 2022 Earnings Call Transcript

Hello, everyone, and thank you for joining the Invitae's third quarter 2022 financial results conference call. Joining us today are president and CEO, Ken Knight; and our CFO, Roxi Wen. Before we begin, I'd like to remind you the various remarks that we make on this call that are not historical, including those about our vision and business model, the company's strategic business realignment, future financial and operating results, expectations of future growth and reduction in burn rate and future products, services, our product pipeline, and the timing constitute forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act.

Yahoo | November 9, 2022

Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates

Invitae (NVTA) delivered earnings and revenue surprises of 28.81% and 0.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022

Invitae Reports Third Quarter 2022 Financial Results

Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2022.

Yahoo | November 8, 2022

Could Invitae Stock Help You Retire a Millionaire?

There's significant growth potential in the genetic testing market, but is Invitae in a good position to take advantage of it?

Yahoo | November 5, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5321 seconds.